Omission of adverse event reporting on finerenone
preprint
OA: closed
Abstract
We wish to describe the omission of adverse event reporting on finerenone in a recently published trial. We suspect that this case illustrates the tip of an iceberg of underreporting of adverse events in clinical trials. We propose as a requirement in clinical trials, to have routine direct reporting by patients for safety monitoring.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-05-19T01:45:01.086888+00:00